Phathom Pharmaceuticals Inc expected to post a loss of 89 cents a share - Earnings Preview

Phathom Pharmaceuticals

03/11/2023 12:55

* Phathom Pharmaceuticals Inc  PHAT.OQ   PHAT.O  is expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Phathom
Pharmaceuticals
Inc is for a loss of 89 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 2.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $23​, above​ its last closing price
of $7.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.94       -0.98      -0.84     Beat    14.2
 Mar. 31 2023  -1.23       -1.26      -0.89     Beat    29.4
 Dec. 31 2022  -1.34       -1.35      -1.33     Beat    1.6​
 Sep. 30 2022  -1.32       -1.32      -1.32     Met     -0.2
 ​​Jun.        -0.99       -1.03      -1.33     Missed  -29.1
 30 2022                                                
 Mar. 31 2022  -0.98       -0.97      -1.07     Missed  -10.5​
 Dec. 31 2021  -1.05       -1.03      -0.95     Beat    7.6
 Sep. 30 2021  -1.01       -0.98      -0.98     Met     0
 This summary was machine generated November 3 at 12:55 GMT.  All
figures in US dollars  unless otherwise stated